查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1873681

注意力不足过动症（ADHD）－全球市场占有率和排名、总收入和需求预测（2025-2031年）

Attention Deficit Hyperactivity Disorder (ADHD) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 105 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024 年全球注意力不足过动症 (ADHD) 市场规模估计为 134.3 亿美元，预计到 2031 年将成长至 185.5 亿美元，2025 年至 2031 年的复合年增长率为 4.9%。

有效治疗注意力不足过动症。注意力不足过动症是指一组始于儿童的综合征，其特征是注意力难以集中、注意力持续时间短，以及与同龄人相比表现出过动或衝动。

由于全球对注意力不足过动症（ADHD）的认知度和诊断率不断提高，尤其是在儿童和青少年群体中，ADHD市场正在迅速扩张。医疗保健专业人员、相关人员和家长对心理健康状况的了解不断加深，有助于更早发现多动症并采取更积极的治疗方法。政府资助的措施、学校心理健康筛检以及保险覆盖范围的扩大，都提高了已开发国家和开发中国家ADHD患者获得治疗的机会。此外，药理学研究的进步使得更有效、更持久、耐受性更好的药物得以问世，从而拓宽了治疗选择的范围。数位健康平台的兴起，包括远端医疗和用于症状监测的行动应用程序，也使ADHD的管理更加便捷高效。公众讨论的增加和对ADHD污名化的减少，推动了成人ADHD诊断数量的上升，进一步促进了市场成长。

儘管需求不断成长，但过动症市场仍面临许多重大挑战。其中一个主要问题是过动症可能被过度诊断或误诊，尤其是在儿童中，这可能导致不恰当或过量用药。区分过动症与其他行为和心理障碍（例如焦虑症、自闭症和学习障碍）仍然十分复杂，通常需要多学科评估。药物副作用，例如失眠、食慾抑制和心血管问题，可能导致患者不遵医嘱甚至中断治疗。由于滥用和依赖的风险，处方兴奋剂也面临监管障碍。此外，低收入和农村地区医疗基础设施的不完善以及训练有素的心理健康专业资源有限，阻碍了及时诊断和治疗。对精神疾病的文化歧视仍然是许多个人和家庭寻求医疗协助的障碍，尤其是在新兴市场。

本报告旨在按地区/国家、类型和分销管道对全球注意力不足过动症 (ADHD) 市场进行全面分析，重点关注总收入、市场份额和主要企业的排名。

注意力不足过动症 (ADHD) 市场规模、估计值和预测以收益为准，以 2024 年为基准年，并包含 2020 年至 2031 年的历史资料和预测资料。报告采用定量和定性分析相结合的方法，帮助读者制定业务/成长策略，评估市场竞争格局，分析公司在当前市场中的地位，并就注意力不足过动症 (ADHD) 做出明智的商业决策。

市场区隔

公司

  • Takeda
  • Johnson & Johnson
  • Novartis
  • Eli Lilly
  • Tris Pharma
  • Neos Therapeutics
  • Mallinckrodt
  • Amneal Pharmaceuticals
  • Noven Pharmaceuticals
  • Purdue Parma
  • Zhengdafenhai
  • Highland Therapeutics
  • Jubilant Life Sciences
  • Medice Arzneimittel Putter
  • Lannett

按类型分類的细分市场

  • 兴奋剂
  • 无刺激性

按分销管道细分

  • 医院药房
  • 零售药房

按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 东南亚
    • 印度
    • 澳洲
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 荷兰
    • 北欧国家
    • 其他欧洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中东和非洲
    • 土耳其
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他中东和非洲地区

The global market for Attention Deficit Hyperactivity Disorder (ADHD) was estimated to be worth US$ 13430 million in 2024 and is forecast to a readjusted size of US$ 18550 million by 2031 with a CAGR of 4.9% during the forecast period 2025-2031.

Effective treatment of ADHD. ADHD refers to a group of syndromes that occur in childhood and are characterized by obvious difficulty in concentration, short duration of attention, hyperactivity or impulsivity compared with children of the same age.

The ADHD market is expanding rapidly due to rising global awareness and increasing diagnosis rates, especially in children and young adults. Improved understanding of mental health conditions among healthcare providers, educators, and parents has contributed to earlier identification and more proactive treatment approaches. Government-supported initiatives, mental health screenings in schools, and expanded insurance coverage have made ADHD treatment more accessible in both developed and developing regions. Furthermore, advancements in pharmacological research have led to the availability of more effective, long-acting, and better-tolerated medications, expanding the range of treatment options. The rise of digital health platforms, including telemedicine and mobile apps for symptom monitoring, has also made ADHD management more convenient and efficient. Growing adult ADHD diagnosis, driven by increased public discussion and reduced stigma, is further contributing to market growth.

Despite the increasing demand, the ADHD market faces several significant challenges. One of the main concerns is the potential overdiagnosis or misdiagnosis of ADHD, particularly in children, leading to inappropriate or excessive use of medications. Differentiating ADHD from other behavioral or psychological disorders like anxiety, autism, or learning disabilities remains complex, often requiring multidisciplinary assessments. Medication side effects, such as insomnia, appetite suppression, and cardiovascular concerns, can lead to treatment non-compliance or discontinuation. There are also regulatory barriers around stimulant drug prescriptions due to their potential for abuse and dependency. Additionally, disparities in healthcare infrastructure and limited access to trained mental health professionals in low-income and rural areas hinder timely diagnosis and treatment. Cultural stigma around psychiatric disorders still discourages many individuals and families from seeking medical help, especially in emerging markets.

This report aims to provide a comprehensive presentation of the global market for Attention Deficit Hyperactivity Disorder (ADHD), focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Attention Deficit Hyperactivity Disorder (ADHD) by region & country, by Type, and by Distribution Channel.

The Attention Deficit Hyperactivity Disorder (ADHD) market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Attention Deficit Hyperactivity Disorder (ADHD).

Market Segmentation

By Company

  • Takeda
  • Johnson & Johnson
  • Novartis
  • Eli Lilly
  • Tris Pharma
  • Neos Therapeutics
  • Mallinckrodt
  • Amneal Pharmaceuticals
  • Noven Pharmaceuticals
  • Purdue Parma
  • Zhengdafenhai
  • Highland Therapeutics
  • Jubilant Life Sciences
  • Medice Arzneimittel Putter
  • Lannett

Segment by Type

  • Stimulant
  • Non-stimulant

Segment by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Attention Deficit Hyperactivity Disorder (ADHD) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Distribution Channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Attention Deficit Hyperactivity Disorder (ADHD) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Attention Deficit Hyperactivity Disorder (ADHD) in country level. It provides sigmate data by Type, and by Distribution Channel for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Attention Deficit Hyperactivity Disorder (ADHD) Product Introduction
  • 1.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Market Size Forecast (2020-2031)
  • 1.3 Attention Deficit Hyperactivity Disorder (ADHD) Market Trends & Drivers
    • 1.3.1 Attention Deficit Hyperactivity Disorder (ADHD) Industry Trends
    • 1.3.2 Attention Deficit Hyperactivity Disorder (ADHD) Market Drivers & Opportunity
    • 1.3.3 Attention Deficit Hyperactivity Disorder (ADHD) Market Challenges
    • 1.3.4 Attention Deficit Hyperactivity Disorder (ADHD) Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Players Revenue Ranking (2024)
  • 2.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Revenue by Company (2020-2025)
  • 2.3 Key Companies Attention Deficit Hyperactivity Disorder (ADHD) Manufacturing Base Distribution and Headquarters
  • 2.4 Key Companies Attention Deficit Hyperactivity Disorder (ADHD) Product Offered
  • 2.5 Key Companies Time to Begin Mass Production of Attention Deficit Hyperactivity Disorder (ADHD)
  • 2.6 Attention Deficit Hyperactivity Disorder (ADHD) Market Competitive Analysis
    • 2.6.1 Attention Deficit Hyperactivity Disorder (ADHD) Market Concentration Rate (2020-2025)
    • 2.6.2 Global 5 and 10 Largest Companies by Attention Deficit Hyperactivity Disorder (ADHD) Revenue in 2024
    • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Attention Deficit Hyperactivity Disorder (ADHD) as of 2024)
  • 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 Stimulant
    • 3.1.2 Non-stimulant
  • 3.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type
    • 3.2.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, by Type (2020-2031)
    • 3.2.3 Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, by Type (%) (2020-2031)

4 Segmentation by Distribution Channel

  • 4.1 Introduction by Distribution Channel
    • 4.1.1 Hospital Pharmacy
    • 4.1.2 Retail Pharmacy
  • 4.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel
    • 4.2.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel (2020 VS 2024 VS 2031)
    • 4.2.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, by Distribution Channel (2020-2031)
    • 4.2.3 Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, by Distribution Channel (%) (2020-2031)

5 Segmentation by Region

  • 5.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Region
    • 5.1.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Region (2020-2025)
    • 5.1.3 Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Region (2026-2031)
    • 5.1.4 Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Region (%), (2020-2031)
  • 5.2 North America
    • 5.2.1 North America Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, 2020-2031
    • 5.2.2 North America Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Country (%), 2024 VS 2031
  • 5.3 Europe
    • 5.3.1 Europe Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, 2020-2031
    • 5.3.2 Europe Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Country (%), 2024 VS 2031
  • 5.4 Asia Pacific
    • 5.4.1 Asia Pacific Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, 2020-2031
    • 5.4.2 Asia Pacific Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Region (%), 2024 VS 2031
  • 5.5 South America
    • 5.5.1 South America Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, 2020-2031
    • 5.5.2 South America Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Country (%), 2024 VS 2031
  • 5.6 Middle East & Africa
    • 5.6.1 Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, 2020-2031
    • 5.6.2 Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Attention Deficit Hyperactivity Disorder (ADHD) Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, 2020-2031
    • 6.3.2 United States Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, 2020-2031
    • 6.4.2 Europe Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, 2020-2031
    • 6.5.2 China Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, 2020-2031
    • 6.6.2 Japan Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, 2020-2031
    • 6.7.2 South Korea Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, 2020-2031
    • 6.9.2 India Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel, 2024 VS 2031

7 Company Profiles

  • 7.1 Takeda
    • 7.1.1 Takeda Profile
    • 7.1.2 Takeda Main Business
    • 7.1.3 Takeda Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.1.4 Takeda Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.1.5 Takeda Recent Developments
  • 7.2 Johnson & Johnson
    • 7.2.1 Johnson & Johnson Profile
    • 7.2.2 Johnson & Johnson Main Business
    • 7.2.3 Johnson & Johnson Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.2.4 Johnson & Johnson Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.2.5 Johnson & Johnson Recent Developments
  • 7.3 Novartis
    • 7.3.1 Novartis Profile
    • 7.3.2 Novartis Main Business
    • 7.3.3 Novartis Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.3.4 Novartis Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.3.5 Novartis Recent Developments
  • 7.4 Eli Lilly
    • 7.4.1 Eli Lilly Profile
    • 7.4.2 Eli Lilly Main Business
    • 7.4.3 Eli Lilly Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.4.4 Eli Lilly Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.4.5 Eli Lilly Recent Developments
  • 7.5 Tris Pharma
    • 7.5.1 Tris Pharma Profile
    • 7.5.2 Tris Pharma Main Business
    • 7.5.3 Tris Pharma Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.5.4 Tris Pharma Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.5.5 Tris Pharma Recent Developments
  • 7.6 Neos Therapeutics
    • 7.6.1 Neos Therapeutics Profile
    • 7.6.2 Neos Therapeutics Main Business
    • 7.6.3 Neos Therapeutics Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.6.4 Neos Therapeutics Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.6.5 Neos Therapeutics Recent Developments
  • 7.7 Mallinckrodt
    • 7.7.1 Mallinckrodt Profile
    • 7.7.2 Mallinckrodt Main Business
    • 7.7.3 Mallinckrodt Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.7.4 Mallinckrodt Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.7.5 Mallinckrodt Recent Developments
  • 7.8 Amneal Pharmaceuticals
    • 7.8.1 Amneal Pharmaceuticals Profile
    • 7.8.2 Amneal Pharmaceuticals Main Business
    • 7.8.3 Amneal Pharmaceuticals Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.8.4 Amneal Pharmaceuticals Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.8.5 Amneal Pharmaceuticals Recent Developments
  • 7.9 Noven Pharmaceuticals
    • 7.9.1 Noven Pharmaceuticals Profile
    • 7.9.2 Noven Pharmaceuticals Main Business
    • 7.9.3 Noven Pharmaceuticals Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.9.4 Noven Pharmaceuticals Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.9.5 Noven Pharmaceuticals Recent Developments
  • 7.10 Purdue Parma
    • 7.10.1 Purdue Parma Profile
    • 7.10.2 Purdue Parma Main Business
    • 7.10.3 Purdue Parma Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.10.4 Purdue Parma Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.10.5 Purdue Parma Recent Developments
  • 7.11 Zhengdafenhai
    • 7.11.1 Zhengdafenhai Profile
    • 7.11.2 Zhengdafenhai Main Business
    • 7.11.3 Zhengdafenhai Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.11.4 Zhengdafenhai Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.11.5 Zhengdafenhai Recent Developments
  • 7.12 Highland Therapeutics
    • 7.12.1 Highland Therapeutics Profile
    • 7.12.2 Highland Therapeutics Main Business
    • 7.12.3 Highland Therapeutics Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.12.4 Highland Therapeutics Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.12.5 Highland Therapeutics Recent Developments
  • 7.13 Jubilant Life Sciences
    • 7.13.1 Jubilant Life Sciences Profile
    • 7.13.2 Jubilant Life Sciences Main Business
    • 7.13.3 Jubilant Life Sciences Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.13.4 Jubilant Life Sciences Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.13.5 Jubilant Life Sciences Recent Developments
  • 7.14 Medice Arzneimittel Putter
    • 7.14.1 Medice Arzneimittel Putter Profile
    • 7.14.2 Medice Arzneimittel Putter Main Business
    • 7.14.3 Medice Arzneimittel Putter Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.14.4 Medice Arzneimittel Putter Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.14.5 Medice Arzneimittel Putter Recent Developments
  • 7.15 Lannett
    • 7.15.1 Lannett Profile
    • 7.15.2 Lannett Main Business
    • 7.15.3 Lannett Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
    • 7.15.4 Lannett Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) & (2020-2025)
    • 7.15.5 Lannett Recent Developments

8 Industry Chain Analysis

  • 8.1 Attention Deficit Hyperactivity Disorder (ADHD) Industrial Chain
  • 8.2 Attention Deficit Hyperactivity Disorder (ADHD) Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Attention Deficit Hyperactivity Disorder (ADHD) Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Attention Deficit Hyperactivity Disorder (ADHD) Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Attention Deficit Hyperactivity Disorder (ADHD) Market Trends
  • Table 2. Attention Deficit Hyperactivity Disorder (ADHD) Market Drivers & Opportunity
  • Table 3. Attention Deficit Hyperactivity Disorder (ADHD) Market Challenges
  • Table 4. Attention Deficit Hyperactivity Disorder (ADHD) Market Restraints
  • Table 5. Global Attention Deficit Hyperactivity Disorder (ADHD) Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Attention Deficit Hyperactivity Disorder (ADHD) Revenue Market Share by Company (2020-2025)
  • Table 7. Key Companies Attention Deficit Hyperactivity Disorder (ADHD) Manufacturing Base Distribution and Headquarters
  • Table 8. Key Companies Attention Deficit Hyperactivity Disorder (ADHD) Product Type
  • Table 9. Key Companies Time to Begin Mass Production of Attention Deficit Hyperactivity Disorder (ADHD)
  • Table 10. Global Attention Deficit Hyperactivity Disorder (ADHD) Companies Market Concentration Ratio (CR5 and HHI)
  • Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Attention Deficit Hyperactivity Disorder (ADHD) as of 2024)
  • Table 12. Mergers & Acquisitions, Expansion Plans
  • Table 13. Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 14. Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type (2020-2025) & (US$ Million)
  • Table 15. Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type (2026-2031) & (US$ Million)
  • Table 16. Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Market Share in Value by Type (2020-2025)
  • Table 17. Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Market Share in Value by Type (2026-2031)
  • Table 18. Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 19. Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel (2020-2025) & (US$ Million)
  • Table 20. Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel (2026-2031) & (US$ Million)
  • Table 21. Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Market Share in Value by Distribution Channel (2020-2025)
  • Table 22. Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Market Share in Value by Distribution Channel (2026-2031)
  • Table 23. Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 24. Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Region (2020-2025) & (US$ Million)
  • Table 25. Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Region (2026-2031) & (US$ Million)
  • Table 26. Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Region (2020-2025) & (%)
  • Table 27. Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Region (2026-2031) & (%)
  • Table 28. Key Countries/Regions Attention Deficit Hyperactivity Disorder (ADHD) Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 29. Key Countries/Regions Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, (2020-2025) & (US$ Million)
  • Table 30. Key Countries/Regions Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, (2026-2031) & (US$ Million)
  • Table 31. Takeda Basic Information List
  • Table 32. Takeda Description and Business Overview
  • Table 33. Takeda Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
  • Table 34. Revenue (US$ Million) in Attention Deficit Hyperactivity Disorder (ADHD) Business of Takeda (2020-2025)
  • Table 35. Takeda Recent Developments
  • Table 36. Johnson & Johnson Basic Information List
  • Table 37. Johnson & Johnson Description and Business Overview
  • Table 38. Johnson & Johnson Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
  • Table 39. Revenue (US$ Million) in Attention Deficit Hyperactivity Disorder (ADHD) Business of Johnson & Johnson (2020-2025)
  • Table 40. Johnson & Johnson Recent Developments
  • Table 41. Novartis Basic Information List
  • Table 42. Novartis Description and Business Overview
  • Table 43. Novartis Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
  • Table 44. Revenue (US$ Million) in Attention Deficit Hyperactivity Disorder (ADHD) Business of Novartis (2020-2025)
  • Table 45. Novartis Recent Developments
  • Table 46. Eli Lilly Basic Information List
  • Table 47. Eli Lilly Description and Business Overview
  • Table 48. Eli Lilly Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
  • Table 49. Revenue (US$ Million) in Attention Deficit Hyperactivity Disorder (ADHD) Business of Eli Lilly (2020-2025)
  • Table 50. Eli Lilly Recent Developments
  • Table 51. Tris Pharma Basic Information List
  • Table 52. Tris Pharma Description and Business Overview
  • Table 53. Tris Pharma Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
  • Table 54. Revenue (US$ Million) in Attention Deficit Hyperactivity Disorder (ADHD) Business of Tris Pharma (2020-2025)
  • Table 55. Tris Pharma Recent Developments
  • Table 56. Neos Therapeutics Basic Information List
  • Table 57. Neos Therapeutics Description and Business Overview
  • Table 58. Neos Therapeutics Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
  • Table 59. Revenue (US$ Million) in Attention Deficit Hyperactivity Disorder (ADHD) Business of Neos Therapeutics (2020-2025)
  • Table 60. Neos Therapeutics Recent Developments
  • Table 61. Mallinckrodt Basic Information List
  • Table 62. Mallinckrodt Description and Business Overview
  • Table 63. Mallinckrodt Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
  • Table 64. Revenue (US$ Million) in Attention Deficit Hyperactivity Disorder (ADHD) Business of Mallinckrodt (2020-2025)
  • Table 65. Mallinckrodt Recent Developments
  • Table 66. Amneal Pharmaceuticals Basic Information List
  • Table 67. Amneal Pharmaceuticals Description and Business Overview
  • Table 68. Amneal Pharmaceuticals Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
  • Table 69. Revenue (US$ Million) in Attention Deficit Hyperactivity Disorder (ADHD) Business of Amneal Pharmaceuticals (2020-2025)
  • Table 70. Amneal Pharmaceuticals Recent Developments
  • Table 71. Noven Pharmaceuticals Basic Information List
  • Table 72. Noven Pharmaceuticals Description and Business Overview
  • Table 73. Noven Pharmaceuticals Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
  • Table 74. Revenue (US$ Million) in Attention Deficit Hyperactivity Disorder (ADHD) Business of Noven Pharmaceuticals (2020-2025)
  • Table 75. Noven Pharmaceuticals Recent Developments
  • Table 76. Purdue Parma Basic Information List
  • Table 77. Purdue Parma Description and Business Overview
  • Table 78. Purdue Parma Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
  • Table 79. Revenue (US$ Million) in Attention Deficit Hyperactivity Disorder (ADHD) Business of Purdue Parma (2020-2025)
  • Table 80. Purdue Parma Recent Developments
  • Table 81. Zhengdafenhai Basic Information List
  • Table 82. Zhengdafenhai Description and Business Overview
  • Table 83. Zhengdafenhai Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
  • Table 84. Revenue (US$ Million) in Attention Deficit Hyperactivity Disorder (ADHD) Business of Zhengdafenhai (2020-2025)
  • Table 85. Zhengdafenhai Recent Developments
  • Table 86. Highland Therapeutics Basic Information List
  • Table 87. Highland Therapeutics Description and Business Overview
  • Table 88. Highland Therapeutics Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
  • Table 89. Revenue (US$ Million) in Attention Deficit Hyperactivity Disorder (ADHD) Business of Highland Therapeutics (2020-2025)
  • Table 90. Highland Therapeutics Recent Developments
  • Table 91. Jubilant Life Sciences Basic Information List
  • Table 92. Jubilant Life Sciences Description and Business Overview
  • Table 93. Jubilant Life Sciences Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
  • Table 94. Revenue (US$ Million) in Attention Deficit Hyperactivity Disorder (ADHD) Business of Jubilant Life Sciences (2020-2025)
  • Table 95. Jubilant Life Sciences Recent Developments
  • Table 96. Medice Arzneimittel Putter Basic Information List
  • Table 97. Medice Arzneimittel Putter Description and Business Overview
  • Table 98. Medice Arzneimittel Putter Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
  • Table 99. Revenue (US$ Million) in Attention Deficit Hyperactivity Disorder (ADHD) Business of Medice Arzneimittel Putter (2020-2025)
  • Table 100. Medice Arzneimittel Putter Recent Developments
  • Table 101. Lannett Basic Information List
  • Table 102. Lannett Description and Business Overview
  • Table 103. Lannett Attention Deficit Hyperactivity Disorder (ADHD) Products, Services and Solutions
  • Table 104. Revenue (US$ Million) in Attention Deficit Hyperactivity Disorder (ADHD) Business of Lannett (2020-2025)
  • Table 105. Lannett Recent Developments
  • Table 106. Key Raw Materials Lists
  • Table 107. Raw Materials Key Suppliers Lists
  • Table 108. Attention Deficit Hyperactivity Disorder (ADHD) Downstream Customers
  • Table 109. Attention Deficit Hyperactivity Disorder (ADHD) Distributors List
  • Table 110. Research Programs/Design for This Report
  • Table 111. Key Data Information from Secondary Sources
  • Table 112. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Attention Deficit Hyperactivity Disorder (ADHD) Product Picture
  • Figure 2. Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Attention Deficit Hyperactivity Disorder (ADHD) Report Years Considered
  • Figure 5. Global Attention Deficit Hyperactivity Disorder (ADHD) Players Revenue Ranking (2024) & (US$ Million)
  • Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Attention Deficit Hyperactivity Disorder (ADHD) Revenue in 2024
  • Figure 7. Attention Deficit Hyperactivity Disorder (ADHD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 8. Stimulant Picture
  • Figure 9. Non-stimulant Picture
  • Figure 10. Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 11. Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value Market Share by Type, 2024 & 2031
  • Figure 12. Product Picture of Hospital Pharmacy
  • Figure 13. Product Picture of Retail Pharmacy
  • Figure 14. Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 15. Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Value Market Share by Distribution Channel, 2024 & 2031
  • Figure 16. North America Attention Deficit Hyperactivity Disorder (ADHD) Sales Value (2020-2031) & (US$ Million)
  • Figure 17. North America Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Country (%), 2024 VS 2031
  • Figure 18. Europe Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, (2020-2031) & (US$ Million)
  • Figure 19. Europe Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Country (%), 2024 VS 2031
  • Figure 20. Asia Pacific Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, (2020-2031) & (US$ Million)
  • Figure 21. Asia Pacific Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Region (%), 2024 VS 2031
  • Figure 22. South America Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, (2020-2031) & (US$ Million)
  • Figure 23. South America Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Country (%), 2024 VS 2031
  • Figure 24. Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, (2020-2031) & (US$ Million)
  • Figure 25. Middle East & Africa Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Country (%), 2024 VS 2031
  • Figure 26. Key Countries/Regions Attention Deficit Hyperactivity Disorder (ADHD) Sales Value (%), (2020-2031)
  • Figure 27. United States Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, (2020-2031) & (US$ Million)
  • Figure 28. United States Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type (%), 2024 VS 2031
  • Figure 29. United States Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel (%), 2024 VS 2031
  • Figure 30. Europe Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. Europe Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type (%), 2024 VS 2031
  • Figure 32. Europe Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel (%), 2024 VS 2031
  • Figure 33. China Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, (2020-2031) & (US$ Million)
  • Figure 34. China Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type (%), 2024 VS 2031
  • Figure 35. China Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel (%), 2024 VS 2031
  • Figure 36. Japan Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, (2020-2031) & (US$ Million)
  • Figure 37. Japan Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type (%), 2024 VS 2031
  • Figure 38. Japan Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel (%), 2024 VS 2031
  • Figure 39. South Korea Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, (2020-2031) & (US$ Million)
  • Figure 40. South Korea Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type (%), 2024 VS 2031
  • Figure 41. South Korea Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel (%), 2024 VS 2031
  • Figure 42. Southeast Asia Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, (2020-2031) & (US$ Million)
  • Figure 43. Southeast Asia Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type (%), 2024 VS 2031
  • Figure 44. Southeast Asia Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel (%), 2024 VS 2031
  • Figure 45. India Attention Deficit Hyperactivity Disorder (ADHD) Sales Value, (2020-2031) & (US$ Million)
  • Figure 46. India Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Type (%), 2024 VS 2031
  • Figure 47. India Attention Deficit Hyperactivity Disorder (ADHD) Sales Value by Distribution Channel (%), 2024 VS 2031
  • Figure 48. Attention Deficit Hyperactivity Disorder (ADHD) Industrial Chain
  • Figure 49. Attention Deficit Hyperactivity Disorder (ADHD) Manufacturing Cost Structure
  • Figure 50. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 51. Bottom-up and Top-down Approaches for This Report
  • Figure 52. Data Triangulation
  • Figure 53. Key Executives Interviewed